Founded with a mission to revolutionize drug delivery systems, Aprecia Pharmaceuticals focuses on developing and manufacturing precision drug delivery products. The company leverages its proprietary 3D printing technology, ZipDose, which allows for the creation of rapidly disintegrating tablets that enhance patient compliance and therapeutic efficacy. Aprecia primarily serves the U.S. market, aiming to maximize the potential of pharmaceutical products through innovative formulation techniques.
Aprecia's notable affiliations include partnerships with leading pharmaceutical companies and investments from prominent healthcare investors. Key achievements include the successful commercialization of the first FDA-approved 3D-printed drug, Spritam, which treats epilepsy. The company's impact is significant in advancing pharmaceutical manufacturing technology, setting new standards for precision and patient-centric drug delivery solutions.
